Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 10;75(1):3.
doi: 10.1186/s43044-022-00326-1.

Novel oral anticoagulant use in adults with congenital heart disease: a single-center experience report

Daniel Samarai  1 , Nazim Isma  1   2 , Sandra Lindstedt  1   3 , Joanna Hlebowicz  4   5
Affiliations

Novel oral anticoagulant use in adults with congenital heart disease: a single-center experience report

Daniel Samarai et al. Egypt Heart J. .

Abstract

Background: Adults with congenital heart disease (ACHD) are a group with an increased risk of thromboembolic complications and arrhythmias. Vitamin K antagonists are the most commonly used thromboprophylaxis therapy in this population. Studies on the efficacy and safety of novel oral anticoagulants (NOAC) are scare in ACHD. A retrospective study on ACHD patients on NOAC treatment registered in the National Quality Registry for Congenital Heart Disease, SWEDCON, and National Quality Registry for Atrial fibrillation and Anticoagulation, AuriculA, from Southern Sweden.

Results: Thirty patients who had been taking NOAC treatment for a minimum of 3 months were included. Their median age was 55 years (SD 17 years) and 57% were male. Median follow-up was 17 months (IQR: 10-41). Eliquis was the most used NOAC (47%). Median CHA2DS2-VASc score was 2 (IQR: 0-3) and HAS-BLED was 1 (IQR: 0-2). Complex ACHD was prevalent in 27% of the patients. No thromboembolic events were recorded; however, one major bleeding, unspecified, was reported during the total cumulative patient follow-up time of 64 years.

Conclusions: The results of our study, although limited in size, suggest that NOAC appear safe and effective in ACHD patients. Further and larger studies on NOAC in ACHD patients are warranted.

Keywords: Atrial fibrillation; Congenital heart disease; Novel oral anticoagulants.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Lanz J, Brophy JM, Therrien J, Kaouache M, Guo L, Marelli AJ. Stroke in adults with congenital heart disease: incidence, cumulative risk, and predictors. Circulation. 2015;132:2385–2394. doi: 10.1161/CIRCULATIONAHA.115.011241. - DOI - PubMed
    1. Verheugt CL, Uiterwaal CSPM, van der Velde ET, Meijboom FJ, Pieper PG, van Dijk APJ, Vliegen HW, Grobbee DE, Mulder BJM. Mortality in adult congenital heart disease. Eur Heart J. 2010;31:1220–1229. doi: 10.1093/eurheartj/ehq032. - DOI - PubMed
    1. Razouki Z, Ozonoff A, Zhao S, Jasuja GK, Rose AJ. Improving quality measurement for anticoagulation: adding international normalized ratio variability to percent time in therapeutic range. Circ Cardiovasc Qual Outcomes. 2014;7:664–669. doi: 10.1161/CIRCOUTCOMES.114.000804. - DOI - PubMed
    1. Samarai D, Isma N, Lindstedt S, Hlebowicz J. Quality and predictors of oral anticoagulation therapy with vitamin K antagonists in adult congenital heart disease: TTR and INR variability. Thromb Res. 2021;207:7–9. doi: 10.1016/j.thromres.2021.08.025. - DOI - PubMed
    1. Samarai D, Lindstedt S, Isma N, Hlebowicz J. Rate and risk factors for thromboembolism and major bleeding in adults with congenital heart disease taking vitamin K antagonist therapy. Thromb Res. 2022;9:100122. doi: 10.1016/j.tru.2022.100122. - DOI

LinkOut - more resources